Munich-based digital medtech company hema.to has closed a €3.6 million funding round to enhance AI-powered blood diagnostics, aimed at improving accuracy and speed in detecting blood cancers.

Target Information

Eindhoven, February 27th, 2025 – hema.to, a Munich-based digital medtech company, has successfully secured €3.6 million in funding. This round was led by LUMO Labs and supported by Bayern Kapital, numerous US angel investors, and previous investors. Hema.to specializes in automating the analysis of complex blood data through AI-powered cytometry, significantly enhancing the efficiency of lab analyses by reducing the time taken from approximately 20 minutes to just 1 minute. This innovation aims to eliminate human subjectivity in detecting conditions such as leukemia and lymphoma, achieving a remarkable reduction of 90% in false negatives related to secondary pathologies.

Leveraging a comprehensive database of over 600,000 files from more than 20 leading centers, hema.to's AI models are CE-marked for clinical-grade performance. With a new end-to-end solution undergoing certification, the company is positioned to assist labs and hospitals across Europe in the diagnosis of blood cancers effectively.

Industry Overview in Europe

The digital health industry in Europe is experiencing rapid growth, driven by advancements in technology that enhance healthcare delivery and patient outcomes. With increasing demands for efficient healthcare solutions, particularly in laboratory diagnostics, companies like hema.to are eme